J.M.P.A. van den Reek
Radboud University Nijmegen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by J.M.P.A. van den Reek.
British Journal of Dermatology | 2014
J.M.P.A. van den Reek; J. Zweegers; Wietske Kievit; M.E. Otero; P.P.M. van Lümig; R.J.B. Driessen; P.M. Ossenkoppele; M.D. Njoo; J.M. Mommers; M.I.A. Koetsier; W.P. Arnold; B.A.M. Sybrandy-Fleuren; A.L.A. Kuijpers; M.P.M. Andriessen; P.C.M. van de Kerkhof; M.M.B. Seyger; E.M.G.J. de Jong
Drug survival is a marker for treatment success. To date, no analyses relating dermatological quality‐of‐life measures to drug survival have been published.
British Journal of Dermatology | 2014
J.M.P.A. van den Reek; P.P.M. van Lümig; R.J.B. Driessen; P.C.M. van de Kerkhof; M.M.B. Seyger; Wietske Kievit; E.M.G.J. de Jong
Long‐term data of etanercept drug survival in patients with psoriasis in daily practice are scarce.
Journal of The European Academy of Dermatology and Venereology | 2015
P.P.M. van Lümig; S.P. Menting; J.M.P.A. van den Reek; Phyllis I. Spuls; P.L.C.M. van Riel; P.C.M. van de Kerkhof; Jaap Fransen; Wietske Kievit; E.M.G.J. de Jong
Concerns exist about a risk of non‐melanoma skin cancer (NMSC) in psoriasis patients and rheumatoid arthritis (RA) patients treated with TNF‐inhibitors. However, current data also show that in some psoriasis patients, NMSC is diagnosed relatively short after the start of TNF‐inhibitors, which suggests that these NMSC can be explained by previous therapies instead of by TNF‐inhibitor therapy.
Journal of The European Academy of Dermatology and Venereology | 2014
J.M.P.A. van den Reek; P.P.M. van Lümig; M Janssen; Henk Schers; Jan C.M. Hendriks; P.C.M. van de Kerkhof; M.M.B. Seyger; E.M.G.J. de Jong
Background Auto‐immune inflammatory rheumatic diseases (AIRD) are often successfully treated with the immunosuppressant azathioprine for years. Treatment with azathioprine has been proven to increase the risk of non‐melanoma skin cancer (NMSC) in transplant patients and possibly in patients with inflammatory bowel disease as well. Little is known about the risk of NMSC in AIRD patients treated with azathioprine.
Journal of The European Academy of Dermatology and Venereology | 2015
J.M.P.A. van den Reek; Marcia Tummers; J. Zweegers; M.M.B. Seyger; P.P.M. van Lümig; R.J.B. Driessen; P.C.M. van de Kerkhof; Wietske Kievit; E.M.G.J. de Jong
Drug survival is an indicator for treatment success; insight in predictors associated with drug survival is important.
British Journal of Dermatology | 2015
J. van der Schaft; Klaziena Politiek; J.M.P.A. van den Reek; Wietske Andrea Christoffers; Wietske Kievit; E.M.G.J. de Jong; Carla A.F.M. Bruijnzeel-Koomen; Marielouise Schuttelaar; M. S. De Bruin-Weller
Long‐term data of ciclosporin A (CsA) treatment in daily practice in patients with severe atopic dermatitis (AD) are lacking.
Journal of Dermatological Treatment | 2013
J.M.P.A. van den Reek; P.P.M. van Lümig; Wietske Kievit; J. Zweegers; P.C.M. van de Kerkhof; M.M.B. Seyger; E.M.G.J. de Jong
Background: To increase effectiveness of standard adalimumab treatment 40 mg every other week (EOW) for patients with psoriasis, dose escalation to 40 mg every week or addition of methotrexate (MTX) are possible strategies. Methods: Daily practice data about adalimumab treatment were extracted from a prospective observational cohort. We analyzed all patients with insufficient efficacy of adalimumab EOW who received 1) adalimumab dose escalation, 2) addition of MTX to adalimumab EOW, or 3) both. Effectiveness was analyzed after 12 and 24 weeks using PASI50, PASI75, and mean differences in PASI. Results: Forty-seven treatment episodes (TE) of adalimumab dose escalations, 11 of MTX addition and six combinations were analyzed. After a first episode of adalimumab dose escalation, 25% and 35% achieved PASI50 after 12 and 24 weeks, respectively. After MTX introduction to adalimumab EOW, 9% and 18% achieved PASI50 after 12 and 24 weeks, respectively. No related serious adverse events were reported. Conclusions:Twenty-five percent of first TE with adalimumab dose escalation induced a PASI50 response after 12 weeks and 35% after 24 weeks. Addition of MTX to adalimumab EOW resulted in PASI50 in 9% after 12 weeks and 18% after 24 weeks. Defining patient-groups that will benefit from these interventions is important.
British Journal of Dermatology | 2017
J. Zweegers; J.M.M. Groenewoud; J.M.P.A. van den Reek; M.E. Otero; P.C.M. van de Kerkhof; R.J.B. Driessen; P.P.M. van Lümig; M.D. Njoo; P.M. Ossenkoppele; J.M. Mommers; M.I.A. Koetsier; W.P. Arnold; M.P.M. Andriessen; A.L.A. Kuijpers; M.A.M. Berends; Wietske Kievit; E.M.G.J. de Jong
The efficacy of etanercept and ustekinumab in psoriasis has been compared in one randomized controlled trial. Comparison of the long‐term effectiveness of biologics in daily‐practice psoriasis treatment is currently lacking.
British Journal of Dermatology | 2016
J. Zweegers; J.M.P.A. van den Reek; P.C.M. van de Kerkhof; M.E. Otero; A.L.A. Kuijpers; M.I.A. Koetsier; W.P. Arnold; M.A.M. Berends; L. Weppner-Parren; P.M. Ossenkoppele; M.D. Njoo; J.M. Mommers; P.P.M. van Lümig; R.J.B. Driessen; Wietske Kievit; E.M.G.J. de Jong
Predictors for successful treatment are important for personalized medicine. Predictors for drug survival of biologics in psoriasis have been assessed, but not split for different biologics or for the reason of discontinuation.
Acta Dermato-venereologica | 2016
J. Zweegers; M.E. Otero; J.M.P.A. van den Reek; P.P.M. van Lümig; R.J.B. Driessen; Wietske Kievit; M.M.B. Seyger; P.C.M. van de Kerkhof; E.M.G.J. de Jong
The efficacy of biologic or conventional systemic therapies for psoriasis has been shown in randomized controlled trials. Effectiveness, however, has been studied in daily practice cohorts, and no aggregation of effectiveness data is available. This systematic review searched PubMed and EMBASE and summarized the real-world evidence on effectiveness of biologics (adalimumab, etanercept, infliximab and ustekinumab) and conventional systemic therapies (acitretin, cyclosporine, fumarates and methotrexate) for the treatment of plaque psoriasis in adults. Thirty-two studies were included. Few data were available on infliximab, ustekinumab and conventional systemics. Results show that biologics and conventional systemics were effective in real-life treatment of psoriasis, with large ranges in the percentage of patients reaching 75% improvement in psoriasis area and severity index score compared with baseline, especially for etanercept and adalimumab treatment. Combination therapies of biologics with conventional systemics, and dose adjustments of biologics were frequently applied strategies and may explain the large range in improvements between cohorts.